Tumor targeting by an aptamer - PubMed (original) (raw)
Affiliations
- PMID: 16595502
Free article
Tumor targeting by an aptamer
Brian J Hicke et al. J Nucl Med. 2006 Apr.
Free article
Abstract
Aptamers are small oligonucleotides that are selected to bind tightly and specifically to a target molecule. We sought to determine whether aptamers have potential for in vivo delivery of radioisotopes or cytotoxic agents.
Methods: TTA1, an aptamer to the extracellular matrix protein tenascin-C, was prepared in fluorescent and radiolabeled forms. After in vivo administration, uptake and tumor distribution of Rhodamine Red-X-labeled aptamer was studied by fluorescence microscopy. In glioblastoma (U251) and breast cancer (MDA-MB-435) tumor xenografts, biodistribution and imaging studies were performed using TTA1 radiolabeled with (99m)Tc. Tenascin-C levels and tumor uptake were studied in a variety of additional human tumor xenografts. To assess the effect of radiometal chelate on biodistribution, mercapto-acetyl diglycine (MAG(2)) was compared with diethylenetriaminepentaacetic acid and with MAG(2)-3,400-molecular-weight PEG (PEG(3,400)).
Results: Intravenous injection of fluorescent aptamer TTA1 produced bright perivascular fluorescence in a xenografted human tumor within 10 min. In the ensuing 3 h, fluorescence diffused throughout the tumor. Labeled with (99m)Tc, TTA1 displayed rapid blood clearance, a half-life of less than 2 min, and rapid tumor penetration: 6% injected dose (%ID)/g at 10 min. Tumor retention was durable, with 2.7 %ID/g at 60 min and a long-lived phase that stabilized at 1 %ID/g. Rapid tumor uptake and blood clearance yielded a tumor-to-blood ratio of 50 within 3 h. Both renal and hepatic clearance pathways were observed. Using the (99m)Tc-labeled aptamer, images of glioblastoma and breast tumors were obtained by planar scintigraphy. Aptamer uptake, seen in several different human tumors, required the presence of the target protein, human tenascin-C. Modification of the MAG(2) radiometal chelator dramatically altered the uptake and clearance patterns.
Conclusion: TTA1 is taken up by a variety of solid tumors including breast, glioblastoma, lung, and colon. Rapid uptake by tumors and rapid clearance from the blood and other nontarget tissues enables clear tumor imaging. As synthetic molecules, aptamers are readily modified in a site-specific manner. A variety of aptamer conjugates accumulate in tumors, suggesting imaging and potentially therapeutic applications.
Comment in
- Using radiolabeled DNA as an imaging agent to recognize protein targets.
Gambhir SS. Gambhir SS. J Nucl Med. 2006 Apr;47(4):557-8. J Nucl Med. 2006. PMID: 16595486 No abstract available.
Similar articles
- Conjugation with (111)In-DTPA-poly(ethylene glycol) improves imaging of anti-EGF receptor antibody C225.
Wen X, Wu QP, Ke S, Ellis L, Charnsangavej C, Delpassand AS, Wallace S, Li C. Wen X, et al. J Nucl Med. 2001 Oct;42(10):1530-7. J Nucl Med. 2001. PMID: 11585869 - Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
Noaparast Z, Hosseinimehr SJ, Piramoon M, Abedi SM. Noaparast Z, et al. J Drug Target. 2015;23(6):497-505. doi: 10.3109/1061186X.2015.1009075. Epub 2015 Feb 12. J Drug Target. 2015. PMID: 25673264 - Using radiolabeled DNA as an imaging agent to recognize protein targets.
Gambhir SS. Gambhir SS. J Nucl Med. 2006 Apr;47(4):557-8. J Nucl Med. 2006. PMID: 16595486 No abstract available. - 99mTc-Mercaptoacetyl-Glu-Glu-aptamer specific for tenascin-C.
Zhang H. Zhang H. 2008 Jul 17 [updated 2008 Aug 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2008 Jul 17 [updated 2008 Aug 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641927 Free Books & Documents. Review. - Clinical aspects of radiolabeled aptamers in diagnostic nuclear medicine: A new class of targeted radiopharmaceuticals.
Farzin L, Shamsipur M, Moassesi ME, Sheibani S. Farzin L, et al. Bioorg Med Chem. 2019 Jun 15;27(12):2282-2291. doi: 10.1016/j.bmc.2018.11.031. Epub 2018 Nov 22. Bioorg Med Chem. 2019. PMID: 30502114 Review.
Cited by
- RNA aptamers and their therapeutic and diagnostic applications.
Germer K, Leonard M, Zhang X. Germer K, et al. Int J Biochem Mol Biol. 2013 Mar 31;4(1):27-40. Print 2013. Int J Biochem Mol Biol. 2013. PMID: 23638319 Free PMC article. - PET imaging of tenascin-C with a radiolabeled single-stranded DNA aptamer.
Jacobson O, Yan X, Niu G, Weiss ID, Ma Y, Szajek LP, Shen B, Kiesewetter DO, Chen X. Jacobson O, et al. J Nucl Med. 2015 Apr;56(4):616-21. doi: 10.2967/jnumed.114.149484. Epub 2015 Feb 19. J Nucl Med. 2015. PMID: 25698784 Free PMC article. - Anti-cancer therapies targeting the tumor stroma.
Hofmeister V, Schrama D, Becker JC. Hofmeister V, et al. Cancer Immunol Immunother. 2008 Jan;57(1):1-17. doi: 10.1007/s00262-007-0365-5. Epub 2007 Jul 27. Cancer Immunol Immunother. 2008. PMID: 17661033 Free PMC article. Review. - Gemcitabine-Incorporated G-Quadruplex Aptamer for Targeted Drug Delivery into Pancreas Cancer.
Park JY, Cho YL, Chae JR, Moon SH, Cho WG, Choi YJ, Lee SJ, Kang WJ. Park JY, et al. Mol Ther Nucleic Acids. 2018 Sep 7;12:543-553. doi: 10.1016/j.omtn.2018.06.003. Epub 2018 Jun 15. Mol Ther Nucleic Acids. 2018. PMID: 30195790 Free PMC article. - Advances in targeted nanotherapeutics: From bioconjugation to biomimicry.
Valcourt DM, Harris J, Riley RS, Dang M, Wang J, Day ES. Valcourt DM, et al. Nano Res. 2018 Oct;11(10):4999-5016. doi: 10.1007/s12274-018-2083-z. Epub 2018 May 17. Nano Res. 2018. PMID: 31772723 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous